FUNDING
Our investors play a major and vital role in the success and growth of our company.
PRIVATE INVESTORS
Prous Institute for Biomedical Research
Prous Institute for Biomedical Research seeks to drive the discovery of new therapies and diagnostic technologies. It combines the development of its own initiatives in the fields of AI, data analysis and drug discovery with strategic partnerships and investments in early-stage biomedical research projects. With more than six decades of experience in the field of life sciences, the Prous Institute has the knowledge and skills to accelerate translational research and, in doing so, improve the health and quality of life of its patients. Our commitment to innovation is built on a collaborative model that fosters partnerships with prestigious academic institutions, government research agencies and benchmark hospital centres. In addition to our internal developments, our investment portfolio currently holds 10 biotechnology and AI companies, including Prous Institute spin-offs.
Inveready
Inveready is one of Spain’s leading alternative asset managers, investing through multiple specialized investment platforms under a single investment philosophy. Founded in 2008, the firm has evolved from its venture capital origins into one of the country’s most active investment managers. Today, Inveready manages more than €2.7 billion in assets, is backed by over 2,000 investors, and has a team of 70 professionals across its offices in San Sebastián, Madrid, and Barcelona. Over more than 18 years of investing, the firm has managed more than 50 funds, backed over 275 companies, and successfully completed more than 80 exits.
Clave Capital
Clave Capital is an independent alternative asset management firm specializing in innovative projects and industrial SMEs, with extensive experience in technology-intensive sectors such as life sciences, healthcare, and advanced industrial technologies. With more than 20 years of experience investing in, building, and supporting technology-driven companies from early stages, the firm has a strong track record in technology transfer and in translating scientific innovation into business value.
Currently, Clave Capital manages €173 million across its investment vehicles. Among these, Clave Innohealth F.C.R. is a €50 million fund focused on medical technologies, established with the support of CDTI Innvierte and several private healthcare investors.
PUBLIC INVESTMENT
CDTI
The Center for Technological Development and Innovation (CDTI, E.P.E.) is the innovation agency of the Ministry of Science, Innovation, and Universities, dedicated to driving technological innovation across the business sector. The CDTI’s mission is to empower the Spanish business ecosystem to transform scientific and technical knowledge into globally competitive, sustainable, and inclusive growth. Under its 2024–2027 Strategic Plan, the CDTI deployed €2.423 billion in 2025 to support Spanish companies and startups.
INNVIERTE Economía Sostenible SICC S.M.E., S.A. is an initiative created by the CDTI, E.P.E. Its aim is to promote business innovation by supporting venture capital investment in technology-based or innovative companies. This entity, established as part of the Spanish Strategy for Science, Technology, and Innovation, is a closed-end, self-managed collective investment company supervised by the National Securities Market Commission.
PUBLIC FUNDING
Retos-Colaboración 2019
El Ministerio de Ciencia, Innovación y Universidades, dentro de la convocatoria de Proyectos de I+D+i «Retos-Colaboración» del Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020, concedió ayuda al proyecto “DESARROLLO DE UNA TERAPIA PARA EL SINDROME X FRÁGIL” liderado por CONNECTA Therapeutics S.L. con número de expediente RTC2019-007230-1. Este proyecto ha sido financiado por el Ministerio de Ciencia, Innovación y Universidades y la Agencia Estatal de Investigación (MCIN/AEI /10.13039/501100011033) dentro del Subprograma RETOS-COLABORACIÓN, Convocatoria 2019. El proyecto está cofinanciado por la Unión Europea con el objetivo de promover el desarrollo tecnológico, la innovación y una investigación de calidad.
The Spanish Ministry of Science, Innovation and Universities, under the call for R + D + i projects “Challenges-Collaboration” of the State Program for Research, Development and Innovation Oriented to Challenges of Society, within the framework of the State Plan for Scientific and Technical Research and Innovation 2017-2020, has granted support to the project “DEVELOPMENT OF A THERAPY FOR FRAGILE X SYNDROME” led by CONNECTA Therapeutics S.L., file number RTC2019-007230-1. The project is funded by the Spanish Ministry of Science, Innovation and Universities, and the State Investigation Agency (MCIN/AEI /10.13039/501100011033) within the RETOS-COLABORACIÓN Subprogram, 2019 Call. The project is co-financed by the European Union with the aim of promoting technological development, innovation and quality research.
Programa NEOTEC 2021
La Presidencia del Centro para el Desarrollo Tecnológico Industrial E.P.E. (CDTI), dentro de la convocatoria «Programa NEOTEC», del procedimiento de concesión de ayudas destinadas a nuevos proyectos empresariales de empresas innovadoras, en el marco del Plan de Recuperación, Transformación y Resiliencia y del Subprograma Estatal de I+D+i Empresarial, concedió ayuda al proyecto “DESARROLLO DE NUEVAS ESTRATEGIAS TERAPÉUTICAS BASADAS EN LA MODULACIÓN DE LA NEUROPLASTICIDAD EN ENFERMEDADES HUÉRFANAS DEL SISTEMA NERVIOSO CENTRAL” liderado por CONNECTA Therapeutics S.L. con número de expediente SNEO-20211088. Este proyecto se encuentra dentro del Programa NEOTEC, Convocatoria 2021 y ha sido subvencionado por el CDTI con la colaboración del Ministerio de Ciencia e Innovación con cargo al Mecanismo de Recuperación y Resiliencia (MRR) de la Unión Europea – Next Generation EU.
The Presidency of the Centre for the Development of Industrial Technology E.P.E (CDTI), as part of the “NEOTEC Programme”, call for proposals for the granting of aid for new business projects by innovative companies, within the framework of the Recovery, Transformation and Resilience Plan and the State Business R+D+I Sub-programme, granted aid to the project “DEVELOPMENT OF NEW THERAPEUTIC STRATEGIES BASED ON THE MODULATION OF NEUROPLASTICITY IN ORPHAN DISEASES OF THE CENTRAL NERVOUS SYSTEM” led by CONNECTA Therapeutics S. L., file number SNEO-20211088. This project is part of the NEOTEC Programme, Call 2021 and has been subsidised by the CDTI with the collaboration of the Ministry of Science and Innovation under the the Recovery and Resilience Mechanism (RRM) of the European Union – Next Generation EU.
ENISA crecimiento
La Empresa Nacional de Innovación, S.M.E., S.A (ENISA), avalada por la Dirección General de Industria y de la Pequeña y Mediana Empresa, integrada, a su vez, en el Ministerio de Industria, Comercio y Turismo, concedió un préstamo participativo al proyecto “Plan de Negocio para solicitud Enisa”, en la línea comercial “ENISA CRECIMIENTO”, liderado por CONNECTA Therapeutics S.L. El proyecto está cofinanciado por la Unión Europea dentro del marco de ayudas del Plan de Recuperación, Transformación y Resiliencia – Next Generation EU, con el objetivo de apoyar los proyectos empresariales basados en un modelo de negocio viable y rentable, que estén buscando una mejora competitiva o un cambio de modelo de su sistema productivo para expandir su negocio o lograr una mejora competitiva.
The Empresa Nacional de Innovación, S.M.E., S.A (ENISA), under management of the General Directorate of Industry and SMEs, itself integrated into the Spanish Government’s Ministry of Industry, Commerce and Tourism, has granted a shareholder loan to the project “Business Plan for Enisa application”, in the commercial line “ENISA GROWTH”, led by CONNECTA Therapeutics S.L. The project is co-financed by the European Union under the framework of the Recovery and Resilience Mechanism – Next Generation Europe, with the aim of supporting business projects based on a viable and profitable business model, which are looking for a competitive improvement or a change of model of their production system to expand their business or achieve a competitive improvement.
Colaboración Público-privada 2022
El Ministerio de Ciencia, Innovación y Universidades, dentro de la convocatoria de Proyectos de I+D+i «Colaboración Público-Privada» del Programa Estatal para impulsar la Investigación Científico-Técnica y su Transferencia, del Plan Estatal de Investigación Científico, Técnica y de Innovación 2021-2023, en el marco del Plan de Recuperación,
Transformación y Resiliencia, concedió ayuda al proyecto “ENSAYO CLÍNICO DE FASE IIA DE UNA TERAPIA INNOVADORA PARA PACIENTES CON SÍNDROME DE X FRÁGIL” liderado por CONNECTA Therapeutics S.L. con número de expediente CPP2022-009659. Este proyecto ha sido financiado por el Ministerio de Ciencia, Innovación y Universidades y la Agencia Estatal de Investigación (MCIN/AEI /10.13039/501100011033) dentro del Subprograma Colaboración Público-Privada, Convocatoria 2022.
The Spanish Ministry of Science, Innovation and Universities, under the call for R + D + i projects “Colaboración Público-Privada” of the State Program for Research, Development and Innovation Oriented to Challenges of Society, within the framework of the State Plan of scientific and technical research and Innovation, has granted support to the project “ENSAYO CLÍNICO DE FASE IIA DE UNA TERAPIA INNOVADORA PARA PACIENTES CON SÍNDROME DE X FRÁGIL” led by CONNECTA Therapeutics S.L., file number CPP2022-009659. The project is funded by the Spanish Ministry of Science, Innovation and Universities, and the State Investigation Agency (MCIN/AEI /10.13039/501100011033) within the Colaboración Público-Privada Subprogram, 2022 Call.
EIC Accelerator Open 2024
El European Innovation Council (EIC), creado por la Comisión Europea, en el marco de Horizon Europe programme (2021-27), bajo la convocatoria HORIZON-EIC-2024-ACCELERATOR-02—EIC Accelerator Open 2024, ha co-financiado el proyecto “FRAXCURE: FRAgile X syndrome Clinical trial: Unravelling the science behind this Rare disease in Europe” liderado por CONNECTA Therapeutics S. L., con número de proyecto 101217931. Este proyecto forma parte de la convocatoria EIC Accelerator, un programa financiado por la Unión Europea para apoyar a las empresas (PYMEs, start-ups, spin-outs y, en casos excepcionales, pequeñas empresas de mediana capitalización) para llevar sus innovaciones al mercado y ampliarlas.
The European Innovation Council (EIC), established by the European Commission, under the Horizon Europe programme (2021-27), under the call HORIZON-EIC-2024-ACCELERATOR-02— EIC Accelerator Open 2024, co-founded the project “FRAXCURE: FRAgile X syndrome Clinical trial: Unravelling the science behind this Rare disease in Europe” led by CONNECTA Therapeutics S. L., with grant agreement number GA 101217931. This project is part of the EIC Accelerator call, an European Union funding programme to support companies (SMEs, start-ups, spin-outs and in exceptional cases small mid-caps) to bring their innovations to market and scale up.
